On January 6, 2020 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, reported that data from studies utilizing Cchek, the company’s artificial intelligence (AI) driven cancer detection technology, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Advances in Liquid Biopsies (Press release, Anixa Biosciences, JAN 6, 2020, View Source [SID1234552708]). The presentation will review data related to Anixa’s recently launched Cchek Prostate Cancer Confirmation test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) conference takes place January 13 – January 16, 2020 at the Hilton Miami Downtown in Miami, Florida and is designed to showcase the latest advances in liquid biopsies and how they may be translated into the clinic. The meeting will be attended by U.S. and international basic scientists, translational researchers, and clinicians.

Details of the poster presentation are as follows:

Abstract title: Using pattern recognition neural networks to detect prostate cancer: a new method to analyze flow cytometry-based immunophenotyping using machine learning
Author: George Dominguez
Session: Poster Session B
Session Date and Start Time: Wednesday, January 15, 2020 at 12:30 p.m. ET

About Cchek
Cchek is an early cancer detection technology, that measures a patient’s immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient’s cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa’s orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek makes it a platform from which multiple cancer diagnostic tests may be developed. On December 16, 2019, Anixa announced the commercial launch of the Cchek Prostate Cancer Confirmation test (Cchek PCC), the first test developed with the Cchek liquid biopsy technology.

On January 6, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that its chief executive officer, Dr. Gerrit Dispersyn, will present at Biotech Showcase 2020 on Monday, January 13, 2020 at 2:00 pm Pacific Time at the Hilton San Francisco Union Square (Press release, Phio Pharmaceuticals, JAN 6, 2020, View Source [SID1234552706]). Phio will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event being held at the Sir Francis Drake Hotel in San Francisco from January 13-15, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation at Biotech Showcase, Dr. Dispersyn will discuss Phio’s proprietary gene-silencing technology INTASYLTM and provide updates on its broad early-stage pipeline applying INTASYL both as a standalone therapy and in combination with adoptive cell-therapy. This will include updates on the Company’s lead product candidates PH-762, designed to silence PD-1 receptor expression on T cells, and PH-804, designed to silence expression of TIGIT on T cells and NK cells.

Details of the presentation are as follows:

Date:

Monday, January 13, 2020

Time:

2:00 p.m. (PST)

Track:

Yosemite C (Ballroom Level)

Location:

Hilton San Francisco Union Square

A live audio webcast of the presentation will be made available on the Events section of the Company’s website at View Source with a replay accessible following the live presentation.

On January 6, 2020 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that Christian Hogg, Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:00pm PST in San Francisco, CA (Press release, Hutchison China MediTech, JAN 6, 2020, View Source [SID1234552705]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter, for 90 days.

On January 6, 2020 Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, reported that it exercised its option to sell $50 million of its common stock to Royalty Pharma, pursuant to the terms of the companies’ recent funding agreements announced on November 4, 2019 (Press release, Epizyme, JAN 6, 2020, View Source [SID1234552704]). The company notified Royalty Pharma that it was exercising the prespecified option when the trailing average share price reached the $20 per share cap. The closing of the sale and issuance of the shares is subject to the satisfaction or waiver of customary conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epizyme expects that this additional capital, combined with its existing cash, cash equivalents and marketable securities on December 31, 2019 of approximately $381 million (preliminary and unaudited), will further support the company’s current operating runway into 2022, which includes the planned epithelioid sarcoma and follicular lymphoma launch activities for tazemetostat, as well as other potential value-creating initiatives.

"2020 is set to be a transformational year as we complete our evolution to a commercial enterprise," said Robert Bazemore, president and chief executive officer of Epizyme. "Our top priorities this year include successfully launching tazemetostat for the first two indications upon approvals, advancing life-cycle development for tazemetostat to support its potential utility in additional treatment settings and combinations, and progressing our research efforts to expand our pipeline. With a strong balance sheet and an exceptional team in place, I am confident in our ability to execute these activities and to realize our mission of rewriting treatment for people with cancer."

Epizyme has outlined the following key milestones for 2020:

Gain U.S. Food and Drug Administration (FDA) approval for and launch tazemetostat for patients with metastatic or locally advanced epithelioid sarcoma in the U.S.;

Gain FDA approval for and launch tazemetostat for patients in the U.S. with relapsed or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations, who have received at least two prior lines of systemic therapy;

Complete the safety evaluation of tazemetostat in combination with doxorubicin and advance the confirmatory trial in the front-line epithelioid sarcoma treatment setting;

Complete the safety evaluation of tazemetostat in combination with "R2" (Revlimid plus Rituximab) and advance the confirmatory trial in the second-line FL treatment setting;

Expand clinical investigation of tazemetostat in combination with R-CHOP in the front-line treatment setting for patients with FL;

Initiate the Phase 2 efficacy portion of the ongoing Phase 1b/2 clinical trial exploring tazemetostat in combination with standard-of-care treatments for chemo-naïve patients with metastatic castration-resistant prostate cancer;

Initiate clinical investigation of tazemetostat in combination with a PARP inhibitor for certain platinum-resistant solid tumors;

Support investigator-sponsored studies designed to evaluate clinical activity of tazemetostat in various combinations for multiple tumor types; and

Pursue additional development candidates for its preclinical programs.

Epizyme’s figure for cash, cash equivalents and marketable securities as of December 31, 2019 is based on preliminary unaudited information and is subject to change as the company has not yet completed its financial closing procedures and its auditors have not reviewed this information.

On January 6, 2020 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, reported that Steve Hoerter, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 11:00 AM PT in San Francisco (Press release, Deciphera Pharmaceuticals, JAN 6, 2020, View Source [SID1234552703]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.